AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
OPKO Health sets $640M-$660M revenue target for 2025, driven by BioReference sale and pipeline advancements.
ByAinvest
Thursday, Jul 31, 2025 9:21 pm ET1min read
OPKO Health is targeting $640M-$660M in revenue for 2025, driven by the sale of its BioReference Health oncology and clinical testing business to Labcorp and advancements in its pipeline. The company is pushing towards profitability through these strategic initiatives.
OPKO Health, Inc. (OPK) reported mixed results for the second quarter of 2025, with revenue declining year-over-year but significant advancements in its pipeline and strategic initiatives aimed at profitability. The company reported $156.8 million in revenue for the quarter, a 13.9% year-over-year decline compared to $182.2 million in Q2 2024 [1][2]. The earnings per share (EPS) for the quarter were -$0.19, compared to -$0.01 a year ago, representing a significant surprise of -58.33% over the consensus estimate of -$0.12 [1][2].Key revenue metrics showed varied performance. Revenue from the transfer of intellectual property and other sources increased by 22% to $15 million, while revenue from products remained relatively stable at $40.7 million, up by 0.5% compared to the same period last year. However, revenue from services decreased by 21.9% to $101.1 million [1][2].
OPKO Health is targeting $640 million to $660 million in revenue for 2025, driven by the sale of its BioReference Health oncology and clinical testing business to LabCorp and advancements in its pipeline [3]. The company is aiming to achieve profitability through these strategic initiatives, which include the development of new therapies and the optimization of existing ones.
Shares of OPKO Health have remained unchanged over the past month, while the Zacks S&P 500 composite has increased by 2.7%. The stock currently holds a Zacks Rank #4 (Sell), indicating potential underperformance in the near term [1][2].
References:
[1] https://finance.yahoo.com/news/compared-estimates-opko-health-opk-230002593.html
[2] https://www.nasdaq.com/articles/compared-estimates-opko-health-opk-q2-earnings-look-key-metrics
[3] https://finance.yahoo.com/news/opko-health-reports-second-quarter-200500684.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet